Literature DB >> 29898968

Association between diabetes and subsequent Parkinson disease: A record-linkage cohort study.

Eduardo De Pablo-Fernandez1, Raph Goldacre1, Julia Pakpoor1, Alastair J Noyce1, Thomas T Warner2.   

Abstract

OBJECTIVE: To investigate the association between type 2 diabetes mellitus (T2DM) and subsequent Parkinson disease (PD).
METHODS: Linked English national Hospital Episode Statistics and mortality data (1999-2011) were used to conduct a retrospective cohort study. A cohort of individuals admitted for hospital care with a coded diagnosis of T2DM was constructed, and compared to a reference cohort. Subsequent PD risk was estimated using Cox regression models. Individuals with a coded diagnosis of cerebrovascular disease, vascular parkinsonism, drug-induced parkinsonism, and normal pressure hydrocephalus were excluded from the analysis.
RESULTS: A total of 2,017,115 individuals entered the T2DM cohort and 6,173,208 entered the reference cohort. There were significantly elevated rates of PD following T2DM (hazard ratio [HR] 1.32, 95% confidence interval [CI] 1.29-1.35; p < 0.001). The relative increase was greater in those with complicated T2DM (HR 1.49, 95% CI 1.42-1.56) and when comparing younger individuals (HR 3.81, 95% CI 2.84-5.11 in age group 25-44 years).
CONCLUSIONS: We report an increased rate of subsequent PD following T2DM in this large cohort study. These findings may reflect shared genetic predisposition and/or disrupted shared pathogenic pathways with potential clinical and therapeutic implications.
© 2018 American Academy of Neurology.

Entities:  

Mesh:

Year:  2018        PMID: 29898968     DOI: 10.1212/WNL.0000000000005771

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  43 in total

1.  Repurposing GLP-1 Receptor Agonists for Parkinson's Disease: Current Evidence and Future Opportunities.

Authors:  Daniella Balduino Victorino; Mariana Nejm; Marcia Guimarães-Marques; Fulvio Alexandre Scorza; Carla Alessandra Scorza
Journal:  Pharmaceut Med       Date:  2021-01-07

2.  Understanding the links between cardiovascular disease and Parkinson's disease.

Authors:  Judy Potashkin; Xuemei Huang; Claudia Becker; Honglei Chen; Thomas Foltynie; Connie Marras
Journal:  Mov Disord       Date:  2019-09-04       Impact factor: 10.338

Review 3.  Drug Repurposing in Parkinson's Disease.

Authors:  Dilan Athauda; Thomas Foltynie
Journal:  CNS Drugs       Date:  2018-08       Impact factor: 5.749

4.  Plasma Metabolomic Markers of Insulin Resistance and Diabetes and Rate of Incident Parkinson's Disease.

Authors:  Samantha Molsberry; Kjetil Bjornevik; Katherine C Hughes; Zhongli Joel Zhang; Sarah Jeanfavre; Clary Clish; Brian Healy; Michael Schwarzschild; Alberto Ascherio
Journal:  J Parkinsons Dis       Date:  2020       Impact factor: 5.568

Review 5.  Neuroprotective Effects of Brain-Gut Peptides: A Potential Therapy for Parkinson's Disease.

Authors:  Dong Dong; Junxia Xie; Jun Wang
Journal:  Neurosci Bull       Date:  2019-07-08       Impact factor: 5.203

Review 6.  Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology.

Authors:  David K Simon; Caroline M Tanner; Patrik Brundin
Journal:  Clin Geriatr Med       Date:  2019-08-24       Impact factor: 3.076

Review 7.  Convergent Molecular Pathways in Type 2 Diabetes Mellitus and Parkinson's Disease: Insights into Mechanisms and Pathological Consequences.

Authors:  Sandeep Xxxx; Mir Hilal Ahmad; Linchi Rani; Amal Chandra Mondal
Journal:  Mol Neurobiol       Date:  2022-05-16       Impact factor: 5.590

Review 8.  Triggers, Facilitators, and Aggravators: Redefining Parkinson's Disease Pathogenesis.

Authors:  Michaela E Johnson; Benjamin Stecher; Viviane Labrie; Lena Brundin; Patrik Brundin
Journal:  Trends Neurosci       Date:  2018-10-17       Impact factor: 13.837

9.  Glucagon-Like Peptide-1 Receptor Agonist Ameliorates 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Neurotoxicity Through Enhancing Mitophagy Flux and Reducing α-Synuclein and Oxidative Stress.

Authors:  Tsu-Kung Lin; Kai-Jung Lin; Hung-Yu Lin; Kai-Lieh Lin; Min-Yu Lan; Pei-Wen Wang; Tzu-Jou Wang; Feng-Sheng Wang; Po-Chin Tsai; Chia-Wei Liou; Jiin-Haur Chuang
Journal:  Front Mol Neurosci       Date:  2021-07-07       Impact factor: 5.639

Review 10.  Approaches to Disease Modification for Parkinson's Disease: Clinical Trials and Lessons Learned.

Authors:  Albert Y Hung; Michael A Schwarzschild
Journal:  Neurotherapeutics       Date:  2020-11-17       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.